Source comparison
Loading Phase vs Maintenance Phase Dosing Protocols
You take Melanotan-1 daily during the loading phase. Typically 5–10 consecutive days. To establish baseline melanin density before transitioning to less frequent maintenance dosing. The loading phase isn't arbitrary; it corresponds to the biological timeline r
This comparison does not assign a generated winner or score.
- You take Melanotan-1 daily during the loading phase. Typically 5–10 consecutive days. To establish baseline melanin density before transitioning to less frequent maintenance dosing. The loading phase isn't arbitrary; it corresponds to the biological timeline required for melanocytes to upregulate tyrosinase, synthesize melanin granules (melanosomes), and transfer those melanosomes to surrounding keratinocytes in the stratum basale and stratum spinosum.
- Standard research protocols use 0.25mg to 1mg per day during loading, injected subcutaneously in the abdomen or thigh. Higher doses (1–2mg) are sometimes used in photodermatosis research (erythropoietic protoporphyria, polymorphic light eruption) where rapid photoprotection is the endpoint, but most pigmentation studies use 0.5–1mg daily to minimize the risk of overshooting melanin density beyond the subject's natural tanning capacity. Doses above 2mg per day have been tested but show diminishing returns. Receptor saturation occurs, and additional peptide doesn't proportionally increase MITF activation.
- After 7–10 days of daily dosing, visible pigmentation becomes apparent in Fitzpatrick skin types II–IV (fair to moderate baseline pigment). At this point, many protocols shift to maintenance dosing: 0.5–1mg every 48–72 hours. The rationale is straightforward. Melanin turnover in the epidermis follows the keratinocyte lifecycle (approximately 28–40 days from basal layer to stratum corneum shedding), so once melanin density is established, you only need periodic receptor stimulation to sustain tyrosinase activity and replace melanin lost to normal epidermal turnover.
- Clinical data from Phase II trials published in British Journal of Dermatology showed that subjects who completed a 10-day loading phase (1mg daily) maintained 70–80% of peak pigmentation for 30–45 days without any further dosing. When maintenance injections were added (1mg every 3 days), pigmentation remained stable for 90+ days. This suggests that you take Melanotan-1 daily during the critical upregulation window, but daily dosing indefinitely is overkill. The tissue-level effect outlasts the peptide's plasma presence by orders of magnitude.
- Protocol customization depends on research objectives. Photoprotection studies targeting erythropoietic protoporphyria (EPP). A genetic condition causing severe phototoxicity. Often use higher loading doses (1.5–2mg daily for 10 days) to achieve maximal melanin density before controlled UV exposure. Cosmetic pigmentation research, by contrast, typically uses lower doses (0.25–0.5mg daily) to achieve gradual, natural-looking tanning without the "overdone" appearance that higher doses can produce in fair-skinned subjects.
- One procedural mistake we see repeatedly: researchers starting maintenance dosing too early, at day 4 or 5, before melanogenesis has fully ramped up. Visible pigmentation lags behind receptor activation by 72–96 hours. If you switch to every-other-day dosing on day 5 because you "see some color," you're likely underdosing during the critical MITF upregulation phase. The result is suboptimal melanin density that plateaus below photoprotective thresholds. Stick to daily dosing through day 7 minimum, day 10 ideally, then transition to maintenance.